Analyst Reco. Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Market Closed - Nyse Other stock markets 01:30:02 15/06/2024 am IST			5-day change	1st Jan Change
13.1 ^USD	+0.15%		-2.75%	-8.20%

14/06	Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	MT
14/06	Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Toyota becomes Asia's most shorted large-cap stock - Hazeltree	12/03	RE
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy	13/02	MT
Brazil's consumer prices forecast to have risen faster in Sept - Reuters poll	10/23/10	RE
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy	03/23/03	MT
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy	22/23/22	MT
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy	31/23/31	MT
TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $20 From $30, Maintains Outperform Rating	16/23/16	MT
TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $30 From $24, Keeps Outperform Rating	04/23/04	MT
BofA Securities Upgrades Takeda Pharmaceutical to Buy From Neutral, Price Target $20	16/23/16	MT
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,000 Yen From 4,600 Yen, Keeps at Buy	06/23/06	MT
Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy	01/22/01	MT
Cowen Upgrades Takeda Pharmaceutical to Outperform From Market Perform	19/22/19	MT
TAKEDA PHARMACEUTICAL : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight From Overweight	07/21/07	MT
Japan Petroleum Exploration : Japanese shares end higher on Wall Street gains, stable U.S. rates	21/21/21	RE
Japanese shares fall on profit booking, checking U.S. rates	06/21/06	RE
Takeda Pharmaceutical : Says Phase 3 Study Results Show Takhzyro Curbed HAE Attack Rate Long Term	13/20/13	MT
Takeda Pharmaceutical Company Limited: Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year	31/19/31	EQ
Takeda Pharmaceutical : Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year	31/19/31	BU
Takeda Pharmaceutical : Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc	03/18/03	BU
Takeda Pharmaceutical : Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and Second Amendment to Bridge Credit Agreement in Connection with Proposed Acquisition of Shire plc	26/18/26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Analyst Reco.

Filters